Non A4 Component Of Amyloid Precursor

Non A4 Component Of Amyloid Precursor Uses, Dosage, Side Effects, Food Interaction and all others data.

Non A4 Component Of Amyloid Precursor is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).

Trade Name Non A4 Component Of Amyloid Precursor
Generic Cinpanemab
Cinpanemab Other Names Cinpanemab, Immunoglobulin g1-lambda, anti-(homo sapiens alpha-synuclein)humanized monoclonal antibody.gamma.1 heavy chain (1-442) (homo sapiens vh (ighv3-25*03 (86%) (ighd)-ighj2*01) (8.10.4) (1-113)-homo sapiens ighg1*03 (ch3(k107>del(443))) (114-442)) (216-213')-, Immunoglobulin g1-lambda, anti-(homo sapiens snca (synuclein alpha, alpha-synuclein, park1, park4, parkinson disease (autosomal dominant, lewy body) 4, non a4 component of amyloid precursor, nacp)), monoclonal antibodygamma1 heavy chain (1-442) (vh (homo, Immunoglobulin g1, anti-(human .alpha.-synuclein) (human monoclonal biib054 .gamma.1-chain), disulfide with human monoclonal biib054 .kappa.-chain, dimer
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Non A4 Component Of Amyloid Precursor
Non A4 Component Of Amyloid Precursor

Innovators Monograph

You find simplified version here Non A4 Component Of Amyloid Precursor


*** Taking medicines without doctor's advice can cause long-term problems.
Share